摘要
目的:系统评价氨氯地平与缬沙坦联合用药治疗原发性高血压的有效性和安全性。方法:计算机检索数据库Cochrane、PubMed、Embase、中国知网(CNKI)、维普(VIP)和万方(Wanfang),检索时限均为建库时间至2015年10月6日。在进行文献质量评估基础上提取文献数据,采用Rev Man 5.3软件进行Meta分析。结果:经过检索并剔除重复文献后共获得54篇文献,最终纳入综述文献21篇。Meta分析结果显示:在降低舒张压、收缩压、有效率、显效率方面联合用药组优于单独使用组,但不良反应发生率明显高于单独使用组。氨氯地平组与缬沙坦组相比,在降低舒张压、显效率、有效率、不良反应发生率方面差异无统计学意义;但在降低收缩压方面,氨氯地平组优于缬沙坦组。结论:氨氯地平和缬沙坦联合使用治疗原发性高血压有显著的疗效,但其安全性有待进一步评价。
Objective： To review effectiveness and safety of amlodipine combined with valsartan for hypertension. Methods： Searching database Cochrane,Pub Med,Embase,CNKI,VIP and Wanfang,the deadline is October 6,2015. Based on quality of literature evaluation,we extract the literature data,using RevMan 5. 3 software. Results： After retrieving and removing duplicate documents obtained after a total of 54 documents,literature review included 21 final. Meta-analysis showed that： in reducing diastolic blood pressure,systolic blood pressure,efficiency,significantly better than the combination of efficiency alone,but significantly higher than the rate of adverse reactions alone. Amlodipine compared to valsartan in reducing diastolic blood pressure,markedly effective,efficient,no significant differences in rates of adverse reactions; but in terms of lowering systolic blood pressure,amlodipine than valsartan. Conclusion： Amlodipine and valsartan in combination with the treatment of primary hypertension have a significant effect,but its safety needs to be further evaluated.
出处
《中国药物评价》
2016年第2期92-100,共9页
Chinese Journal of Drug Evaluation
